Jorge Nieva, MD, Discusses the Impact of IMpower010 and New Trials in Progress for Early-Stage NSCLC

Video
Conference|ASCO Annual Meeting: Lung Cancer

CancerNetwork® sat down with Jorge Nieva, MD, at the 2021 ASCO Annual Meeting to talk about the future of clinical trials for early-stage non–small cell lung cancer.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Jorge Nieva, MD, from Keck School of Medicine of University of Southern California, about how IMpower010 (NCT02486718) made a big impact at this year’s meeting. The trial examined atezolizumab (Tecentriq) and compared it with best supportive care therapy after adjuvant chemotherapy in patients with resected early-stage non–small cell lung cancer. Results from this study indicated that the trial met its primary end point of disease-free survival superiority with atezolizumab (HR, 0.79; 95% CI, 0.64-0.96; 2-sided P = .0205), with overall survival data still immature.

Transcript:

I’m a lung cancer doctor, [and I’m most excited about IMpower010]. I think this will be the biggest splash that comes out [ASCO]. There’s going to be 6 trials in the works asking the same question [of how will adjuvant therapy affect early stage NSCLC]. They’re all going to come out sometime later. I don’t think any of those 6 trials are reporting out at ASCO.

Reference

Wakelee H, Altorki N, Zhou C, et al. IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). J Clin Oncol. 2021;39(suppl 15):8500. doi: 10.1200/JCO.2021.39.15_suppl.8500

Recent Videos
Future work may focus on determining strategies for protecting the health of patients who undergo surgery during climate disasters.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
A study assessed whether physicians would keep patients who received NSCLC surgery in the hospital longer as an improvisational strategy after wildfires.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
6 experts are featured in this series.
6 experts are featured in this series.
Related Content
HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis

HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis

Tim Cortese
March 31st 2025
Article

Muhammed Talha Waheed, MD, stated that a retrospective study found an OS benefit in CRC peritoneal metastasis with cytoreduction surgery without HIPEC vs with HIPEC.

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

Leticia Nogueira, PhD, MPH
March 31st 2025
Podcast

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Local Excision After Chemo Achieves Negative Margins in Rectal Cancer

Local Excision After Chemo Achieves Negative Margins in Rectal Cancer

Tim Cortese
March 31st 2025
Article

A phase 2 trial presented at SSO met its primary end point by achieving negative margins in 79% of patients with node-negative rectal cancer.

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Rahul Banerjee, MD, FACP;Shernan Holtan, MD
March 3rd 2025
Podcast

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.

Findings from the phase 3 CROWN trial evaluating lorlatinib in ALK-positive non–small cell lung cancer revealed a sustained PFS benefit with the agent.

Integrating Lorlatinib Into First-Line ALK-Positive NSCLC Treatment

Roman Fabbricatore
March 29th 2025
Article

Findings from the phase 3 CROWN trial evaluating lorlatinib in ALK-positive non–small cell lung cancer revealed a sustained PFS benefit with the agent.

Leticia Nogueira, PhD, MPH, highlights how facilities exposed to wildfires tend to have longer lengths of stay for patients undergoing surgery for NSCLC.

Prioritizing Climate Hazard Preparedness Following NSCLC Surgery

Russ Conroy
March 28th 2025
Article

Leticia Nogueira, PhD, MPH, highlights how facilities exposed to wildfires tend to have longer lengths of stay for patients undergoing surgery for NSCLC.